BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 35857320)

  • 1. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
    Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
    JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
    Miller OS; Elder EJ; Jones KJ; Gidal BE
    Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products.
    Zamarripa CA; Tilton HE; Lin S; Cone EJ; Winecker RE; Flegel RR; Kuntz D; Beals M; Jacques M; Clark M; Welsh ER; Wagner L; Bonn-Miller MO; Vandrey R; Spindle TR
    J Anal Toxicol; 2024 Mar; 48(2):81-98. PubMed ID: 38217086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
    Gurley BJ; Murphy TP; Gul W; Walker LA; ElSohly M
    J Diet Suppl; 2020; 17(5):599-607. PubMed ID: 32431186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
    Fernández N; Cappello MG; Quiroga PN
    Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercial Delta-8 THC Products: an Analysis of Content and Labeling.
    Kaczor EE; Greene K; Babu KM; Berthold EC; Sharma A; Carreiro SP
    J Med Toxicol; 2024 Jan; 20(1):31-38. PubMed ID: 37917314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Cannabidiol, Δ
    ElSohly MA; Murphy TP; Khan I; Walker LW; Gul W
    Med Cannabis Cannabinoids; 2020 Aug; 3(1):1-13. PubMed ID: 34676337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
    Hammond D; Goodman S
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of cannabinoids in hemp oil based cosmetic products by LC-tandem MS.
    Hsu YH; Fang MC; Huang SC; Kao YM; Tseng SH; Wang DY
    J Food Drug Anal; 2021 Sep; 29(3):502-509. PubMed ID: 35696248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
    PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid, Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements.
    Wakshlag JJ; Cital S; Eaton SJ; Prussin R; Hudalla C
    Vet Med (Auckl); 2020; 11():45-55. PubMed ID: 32346530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.
    Gibson LP; Mueller RL; Winiger EA; Klawitter J; Sempio C; Williams S; Bryan AD; Bidwell LC; Hutchison KE
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):320-334. PubMed ID: 36378267
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
    Moore CF; Weerts EM
    Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
    Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cross-reactivity of cannabinoid analogs (delta-8-THC, delta-10-THC and CBD), their metabolites and chiral carboxy HHC metabolites in urine of six commercially available homogeneous immunoassays.
    Wolf CE; Pokhai AA; Poklis JL; Williams GR
    J Anal Toxicol; 2023 Nov; 47(8):732-736. PubMed ID: 37602947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
    Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new Cannabis genome assembly associates elevated cannabidiol (CBD) with hemp introgressed into marijuana.
    Grassa CJ; Weiblen GD; Wenger JP; Dabney C; Poplawski SG; Timothy Motley S; Michael TP; Schwartz CJ
    New Phytol; 2021 May; 230(4):1665-1679. PubMed ID: 33521943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
    Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.